Palabras clave
anciano
Toxicidad aguda
Toxicidad crónica
quimioterapia
radioterapia
Inmunoterapia
Cómo citar
Resumen
El cáncer es una enfermedad crónica no transmisible que ha ido en aumento dada la transición de la pirámide poblacional, reportando alta prevalencia en mayores de 65 años. Dado la evidencia limitada frente a esquemas de tratamiento en adultos mayores, se han evidenciado desenlaces adversos, como toxicidad, ya sea cutánea, cardiovascular, nefrotóxica o neurológica, compromiso cognitivo y muerte, lo cual impacta la calidad de vida de los pacientes y la adherencia al tratamiento. Se han estudiado diversas escalas de riesgo en oncogeriatría para valoración de toxicidad, sin embargo, no se encuentran validadas en Colombia. En esta primera parte de la serie de dos partes tiene como objetivo sensibilizar a los médicos no oncólogos frente a la detección temprana de síntomas asociados a toxicidad secundarios al tratamiento con quimioterapia, radioterapia e inmunoterapia en pacientes ancianos. La segunda parte presentara herramientas de tamización de riesgo de deterioro en la salud en una persona anciana y los beneficios de una valoración geriátrica integral ante un paciente anciano con cáncer. También se darán unas pautas sobre el proceso rehabilitatorio y el cuidado paliativo.
Verduzco-Aguirre HC, Navarrete-Reyes AP, Negrete-Najar JP, Soto-Pérez-De-Celis E. Cáncer en el adulto mayor en Latinoamérica: cooperación interdisciplinaria entre oncología y geriatría. Rev Salud Pública. 2020;22(3):1-9. https://doi.org/10.15446/rsap.V22n3.84617
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-49. https://doi.org/10.3322/caac.21660
International Agency for Research on Cancer. Colombia: Globocan 2020 [internet]. 2021 [citado 2021 mar 24]. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-65. https://doi.org/10.1200/JCO.2008.20.8983
Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587-94. https://doi.org/10.1200/JCO.2013.55.0418
DeSantis CE, Miller KD, Dale W, Mohile SG, Cohen HJ, Leach CR, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019 Nov 1;69(6):452-67. https://doi.org/10.3322/caac.21577
Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol. 2018;131(June):16-23. https://doi.org/10.1016/j.critrevonc.2018.08.008
Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326-47. http://10.0.4.176/jco.2018.78.8687
Schiefen JK, Madsen LT, Dains JE. Treatment risk in the senior population. J Adv Pract Oncol [internet]. 2017 Jul-Aug;8(5):528-33. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067916/
Beracasa L. Toxicidad relacionada con el tratamiento para el cáncer en adultos mayores. Revisión de la literatura. Univ Med. 2021;62(1). https://doi.org/10.11144/Javeriana.umed62-1.toxi
Kotzerke D, Moritz F, Mantovani L, Hambsch P, Hering K, Kuhnt T, et al. The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer: a prospective clinical study. J Geriatr Oncol. 2019;10(6):937-43.
Wang TQ, Samuel JN, Brown MC, Vennettilli A, Solomon H, Eng L, et al. Routine surveillance of chemotherapy toxicities in cancer patients using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Oncol Ther. 2018;6(2):189-201. https://doi.org/10.1007/s40487-018-0065-7
Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. Cancer Therapy Evaluation Program (CTEP) [internet]. 2017;155. Disponible en: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
Anderson JM. Biocompatibility. En: Polymer science: a comprehensive reference. New York: Elsevier; 2012. p. 363-83.
Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am. 2014;32(1):167-203.
Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of checkpoint inhibitor induced immune-related adverse events—a comprehensive review. Front Oncol. 2021;10(February):1-16.
Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):10-2. https://doi.org/10.1038/s41467-020-17670-y
O’Donovan A, Leech M, Gillham C. Assessment and management of radiotherapy induced toxicity in older patients. J Geriatr Oncol. 2017;8(6):421-7. https://doi.org/10.1016/j.jgo.2017.07.001
Keenan LG, O’Brien M, Ryan T, Dunne M, McArdle O. Assessment of older patients with cancer: Edmonton Frail Scale (EFS) as a predictor of adverse outcomes in older patients undergoing radiotherapy. J Geriatr Oncol. 2017;8(3):206-10. https://doi.org/10.1016/j.jgo.2016.12.006
Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. J Am Heart Assoc. 2020;9(18):e018403. https://doi.org/10.1161/JAHA.120.018403
Pulito C, Cristaudo A, Porta C La, Zapperi S, Blandino G, Morrone A, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. https://doi.org/10.1186/s13046-020-01715-7
Kusiak A, Alicjajereczek-Fossa B, Cichońska D, Alterio D. Oncological-therapy related oral mucositis as an interdisciplinary problem—literature review. Int J Environ Res Public Health. 2020 Apr 3;17(7):2464. https://doi.org/10.3390/ijerph17072464
Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020 May 13;14(1):442. https://doi.org/10.4081/oncol.2020.442
Salzmann M, Marmé F, Hassel JC. Prophylaxis and management of skin toxicities. Breast Care (Basel). 2019 Apr;14(2):72-77. https://doi.org/10.1159/000497232
Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009 Mar;28(1):11-4.
Pinkerton RC, Ph D, Rogers LM. Sequelae and Alopecia Among. 2001;9(6):283-9. https://doi.org/10.1046/j.1523-5394.2001.96007.x
Münstedt K, Manthey N, Sachsse S, Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer. 1997;5(2):139-43. https://doi.org/10.1007/BF01262572
Wang S, Yang T, Shen A, Qiang W, Zhao Z, Zhang F. The scalp cooling therapy for hair loss in breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis. Support Care Cancer. 2021 Nov;29(11):6943-56. https://doi.org/10.1007/s00520-021-06188-8
Brown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. J Oncol Pract. 2020;16(3):103-9. https://doi.org/10.1200/JOP.19.00652
Villa A, Sonis ST. Pharmacotherapy for the management of cancer regimen-related oral mucositis. Expert Opin Pharmacother. 2016;17(13):1801-7. https://doi.org/10.1080/14656566.2016.1217993
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423-31. https://doi.org/10.1002/cncr.33100
Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003 Oct;98(7):1531-9. https://doi.org/10.1002/cncr.11671
Jones JA, Avritscher EBC, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006 Jun;14(6):505-15. https://doi.org/10.1007/s00520-006-0055-4
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007 Mar;109(5):820-31. https://doi.org/10.1002/cncr.22484
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004 May;100(9 Suppl):1995-2025. https://doi.org/10.1002/cncr.20162
Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004 Apr;4(4):277-84.
Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003 Feb;39(2):91-100.
Bensadoun RJ. Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema. Curr Opin Oncol. 2018 Jul;30(4):226-32. https://doi.org/10.1097/CCO.0000000000000452
Al-Rudayni AHM, Gopinath D, Maharajan MK, Veettil SK, Menon RK. Efficacy of photobiomodulation in the treatment of cancer chemotherapy-induced oral mucositis: A meta-analysis with trial sequential analysis. Int J Environ Res Public Health. 2021 Jul 12;18(14):7418. https://doi.org/10.3390/ijerph18147418
Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2022 Mar;171:103575. https://doi.org/10.1016/j.critrevonc.2021.103575
Sarezky J, Sachs G, Elinzano H, Stavros K. Cancer and peripheral nerve disease. Clin Geriatr Med. 2021 May;37(2):289-300. https://doi.org/10.1016/j.cger.2021.01.003
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain [Internet]. 2014;155(12). Disponible en: https://journals.lww.com/pain/fulltext/2014/12000/incidence,_prevalence,_and_predictors_of.6.aspx
Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1306-1319. https://doi.org/10.1016/j.annonc.2020.07.003
Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol. 2015 Oct;28(5):500-7. https://doi.org/10.1097/WCO.0000000000000234
Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book. 2015:e553-60. https://doi.org/10.14694/EdBook_AM.2015.35.e553
Wang AB, Housley SN, Flores AM, Kircher SM, Perreault EJ, Cope TC. A review of movement disorders in chemotherapy-induced neurotoxicity. J Neuroeng Rehabil. 2021 Jan 25;18(1):16. https://doi.org/10.1186/s12984-021-00818-2
Arnold B, Mitchell SA, Lent L, Mendoza TR, Rogak LJ, Barragán NM, et al. Linguistic validation of the Spanish version of the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Support Care Cancer. 2016;24(7):2843-51. https://doi.org/10.1007/s00520-015-3062-5
Derman BA, Davis AM. Recommendations for prevention and management of chemotherapy-induced peripheral neuropathy. JAMA. 2021 Sep 21;326(11):1058-9. https://doi.org/10.1001/jama.2021.7458
Perazella MA. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012 Oct 5;7(10):1713-21.
Małyszko J, Kozłowska K, Kozłowski L, Małyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017 Jun 1;32(6):924-936. https://doi.org/10.1093/ndt/gfw338
Tuch G, Soo WK, Luo KY, Frearson K, Oh EL, Phillips JL, et al. Cognitive assessment tools recommended in geriatric oncology guidelines: a rapid review. Curr Oncol. 2021 Oct 8;28(5):3987-4003. https://doi.org/10.3390/curroncol28050339
Magnuson A, Mohile S, Janelsins M. Cognition and cognitive impairment in older adults with cancer. Curr Geriatr Rep. 2016 Sep;5(3):213-219. https://doi.org/10.1007/s13670-016-0182-9
Mayo SJ, Lustberg M, Dhillon HM, Nakamura ZM, Allen DH, Ah D, et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer. 2021 Jun;29(6):2821-40. https://doi.org/10.1007/s00520-020-05860-9
Magnuson A, Ahles T, Chen BT, Mandelblatt J, Janelsins MC. Cognitive function in older adults with cancer: assessment, management, and research opportunities. J Clin Oncol. 2021;39(19):2138-49. https://doi.org/10.1200/JCO.21.00239
Edelstein A, Pergolizzi D, Alici Y. Cancer-related cognitive impairment in older adults. Curr Opin Support Palliat Care. 2017 Mar;11(1):60-69. https://doi.org/10.1097/SPC.0000000000000254
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2024 Manuel Alejandro Nieto González, Marcela Andrea Osorio Osorio, David José Coca León, Rodrigo Alberto Heredia Ramírez, Yuli Andrea Russi Noguera, Paola Andrea Pinilla, Thalia Lorena Pinilla Aldana, Laura María Méndez Rodríguez, Santiago Andrés Molina Reyes, Daniela Gnecco Patarroyo